MGMax J. Gordon

Max J. Gordon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Max J. Gordon has a total of 191 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pembrolizumab in Relapsed and Refractory Extranodal Diffuse Large B-Cell Lymphomas and Mediastinal Gray-Zone Lymphoma

    by Rahul Lakhotia, Disha Dalela, Max J. Gordon, Christopher Melani, Stefania Pittaluga, Sarah Evans, Elaine S. Jaffe, Mark Roschewski, Wyndham H. Wilson

    PD-1 is an inhibitory receptor on T cells that, when bound by PD-L1 or PD-L2, suppresses anti-tumor immunity. Tumors can exploit this pathway through overexpression of PD-L1, often driven by 9p24.1 chromosomal alterations. Within aggressive lymphomas, Chromosome 9p24.1 alterations occur in approximately 60% of mediastinal gray zone lymphoma (MGZL) cases, 14% of non-germinal center B-cell (non-GCB) diffuse large B-cell lymphomas (DLBCL), and over 50% of primary central nervous system (CNS) lymphoma and primary testicular lymphoma (PTL) cases. Outcomes for relapsed or refractory disease remain dismal across these histologies. Given the frequent chromosome 9p24.1 alterations in these lymphomas, PD-1/PD-L1 inhibition represents a rational therapeutic strategy in these malignancies. We conducted a single-institution, open-label, phase 2 study of time-limited pembrolizumab monotherapy 200 mg every 21 days for up to 2 years (35 cycles) in patients with relapsed or refractory MGZL, primary CNS lymphoma, or DLBCL subtypes that share biologic features with primary CNS lymphoma, including PTL and non-GCB DLBCL with extranodal involvement. Eligible patients were aged ≥14 years with adequate organ function and no prior anti-PD-1/PD-L1 therapy. Disease assessment was performed via CT and/or MRI at baseline, after cycles 2, 6, 13, 17, 26, and 35. The primary endpoint was overall response rate (ORR); secondary endpoints included safety, progression free survival (PFS), and overall survival (OS). The study was terminated early due to slow accrual, and 11 patients were evaluable for response. Patients had a median of 2 prior lines of therapy and histologies included 5 primary CNS lymphoma, 2 MGZL, 2 non-GCB DLBCL without CNS involvement, and 2 non-GCB DLBCL with secondary CNS involvement. Responses were observed in two patients: 1 patient with PCNSL with a partial response and 1 patient with MGZL with a CR that was ongoing at 3 years. Overall, the 2-year PFS was 9.1% and the 2-year OS was 64%. No unexpected toxicities were observed. Single-agent pembrolizumab had limited activity in relapsed or refractory extranodal DLBCL including PCNSL. In PCNSL, this may party reflect the immunosuppressive tumor microenvironment, which can impair effective antitumor T-cell responses despite frequent activation of the PD-1/PD-L1 pathway. Clinical factors may also contribute, as even limited CNS progression can cause significant neurologic symptoms and create an urgent need for disease control, potentially narrowing the therapeutic window for agents with delayed response kinetics such as PD-1 inhibitors. However, a durable CR was observed in the one MGZL patient treated, supporting continued investigation of this treatment in select LBCL subtypes.

  • Open Access

    Immunologic changes during treatment with romidepsin, azacitidine, and lenalidomide in relapse/refractory T-cell lymphoma

    by Max J. Gordon, Logan Cook, Milos D. Miljkovic, Rahul Lakhotia, Christopher Melani, Mark Roschewski, Jagan Muppidi, Irini Sereti, Louis M. Staudt, Wyndham H. Wilson, et al.

  • Open Access

    Meta-analysis of survival by phased-variant ctDNA and PET response in large B-cell lymphoma

    by Max J Gordon, Hyoyoung Choo-Wosoba, Gonca Ozcan, Rahul Lakhotia, Elizabeth Hill, Christopher Melani, Wyndham H Wilson

    Positron emission tomography (PET) is used to assess response in large B cell lymphoma (LBCL) but 20% to 30% of responding patients will relapse. Circulating tumor DNA detected by phased-variants is a highly sensitive means of identifying measurable residual disease (MRD) which may improve PET response assessment. We conducted a meta-analysis of end of treatment MRD and PET in LBCL treated with curative intent frontline therapy. Three studies and 367 patients were included. In the pooled analysis, the hazard ratio (HR) for progression-free survival (PFS) in undetectable vs. detectable MRD was 14.02 (95% CI, 7.35 - 26.74) and 5.09 (95% CI, 3.29 - 7.88) in PET complete metabolic response (CMR) vs. no CMR (p=0.01 for group difference). Two-year PFS rates were 95.7% (95%, CI 89.7% - 98.3%) with undetectable MRD and CMR, 91.3% (95% CI, 84.5% - 95.3%) in undetectable MRD and no CMR, 40.2% (95% CI, 20.9% - 63.2%) in detectable MRD and CMR and 23.4% (95% CI, 11.7% - 41.3%) in detectable MRD and no CMR (p<0.0001 for group differences). Phased-variant detected MRD provides clinically meaningful prognostic information when assessed at end of frontline curative intent chemoimmunotherapy in patients with LBCL independent of PET response assessment.

  • Open Access

    A phase 1 trial of romidepsin, azacitidine, dexamethasone, and lenalidomide in relapsed or refractory T-cell lymphoma

    by Max J. Gordon, Milos D. Miljkovic, Paige Milhon, Rahul Lakhotia, Christopher Melani, Kim Johnson, Bonita R Bryant, Stefania Pittaluga, Elaine S. Jaffe, Kevin C. Conlon, et al.

    Targeted therapies can induce responses in patients with relapsed/refractory T-cell lymphoma (R/R TCL) but are not curative. Genetic mutations associated with epigenetic and transcriptional dysregulation are common in many TCL subtypes, and drugs that modulate the epigenome and that target transcriptional regulators have synergistic activity in TCL. We hypothesized that fixed duration treatment with multiagent combinations of these drugs could produce deep responses leading to durable remissions. In a phase 1 trial, we tested escalating doses of lenalidomide added to romidepsin, azacitidine, and dexamethasone (RAdR) for patients with R/R TCL. The primary objective was to identify the maximum tolerated dose (MTD) of lenalidomide that could safely be used in RAdR. Secondary end points included response rate, survival, and markers of immune activation. Twenty-six patients enrolled and 21 were evaluable for response. Adverse events were predominantly gastrointestinal and hematologic. Grade 3/4 thrombocytopenia and neutropenia occurred in 19% and 21% of cycles, respectively. The MTD of lenalidomide was 20 mg. Among 9 patients treated at the MTD the objective response rate was 89% and complete response rate 22%. At 1 year, the estimated rate of progression-free survival was 14% and overall survival was 66%. Cell line models of anaplastic large cell lymphoma were interrogated to explore the activity of drug combinations in responding genetic subtypes. RAdR demonstrated activity in patients with highly refractory TCL but did not induce durable responses. This novel combination effectively bridged some patients with refractory TCL to consolidation such as allogeneic transplantation. This trial was registered at www.ClinicalTrials.gov as NCT04447027.


  • Open Access

    The anti‐CD47 antibody magrolimab with obinutuzumab and venetoclax in relapsed or refractory indolent B‐cell lymphomas

    by Rahul Lakhotia, Christopher Melani, Stefania Pittaluga, Max J. Gordon, James D. Phelan, Jagan R. Muppidi, Atekelt Tadese, Sarah Evans, Elaine S. Jaffe, Louis M. Staudt, et al.

    Follicular lymphoma (FL), marginal zone lymphoma (MZL), chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL) are characterized by a continuous incidence of relapse and increasing resistance to therapy. Novel immunotherapy approaches are needed. Magrolimab, a CD47-blocking antibody, disrupts CD47:SIRPα-mediated antiphagocytic signalling. When combined with a prophagocytic signal from an anti-CD20 antibody rituximab, it has shown activity in relapsed or refractory FL and MZL. In this phase 1 study, adding the BCL2-inhibitor venetoclax to magrolimab and the anti-CD20 antibody obinutuzumab resulted in complete responses in 6 of 10 (60%) evaluable patients with FL, MZL or CLL. Notably, we did not observe increased risk of infections previously reported from studies of magrolimab in acute myeloid leukaemia and higher risk myelodysplastic syndromes.


  • Open Access

    A phase 1 study of interleukin-15 in combination with mogamulizumab in relapsed and refractory T-cell malignancies

    by Max J. Gordon, Sigrid Dubois, Milos D. Miljkovic, Samuel Ng, Bonita Bryant, Rahul Lakhotia, Christopher Melani, Stefania Pittaluga, Kevin Conlon, Thomas Waldmann, et al.


  • Comparison of Comorbidity Models Within a Population-Based Cohort of Older Adults With Non-Hodgkin Lymphoma

    by Max J. Gordon, Zhigang Duan, Hui Zhao, Loretta Nastoupil, Swaminathan Iyer, Alessandra Ferrajoli, Alexey V. Danilov, Sharon H. Giordano

    PURPOSE: Compare the association of individual comorbidities, comorbidity indices, and survival in older adults with non-Hodgkin lymphoma (NHL), including in specific NHL subtypes. METHODS: Data source was SEER-Medicare, a population-based registry of adults age 65 years and older with cancer. We included all incident cases of NHL diagnosed during 2008-2017 who met study inclusion criteria. Comorbidities were classified using the three-factor risk estimate scale (TRES), Charlson comorbidity index (CCI), and National Cancer Institute (NCI) comorbidity index categories and weights. Overall survival (OS) and lymphoma-specific survival, with death from other causes treated as a competing risk, were estimated using the Kaplan-Meier method from time of diagnosis. Multivariable Cox models were constructed, and Harrel C-statistics were used to compare comorbidity models. A two-sided P value of <.05 was considered significant. RESULTS: A total of 40,486 patients with newly diagnosed NHL were included. Patients with aggressive NHL had higher rates of baseline comorbidity. Despite differences in baseline comorbidity between NHL subtypes, cardiovascular, pulmonary, diabetes, and renal comorbidities were frequent and consistently associated with OS in most NHL subtypes. These categories were used to construct a candidate comorbidity score, the non-Hodgkin lymphoma 5 (NHL-5). Comparing three validated comorbidity scores, TRES, CCI, NCI, and the novel NHL-5 score, we found similar associations with OS and lymphoma-specific survival, which was confirmed in sensitivity analyses by NHL subtypes. CONCLUSION: The optimal measure of comorbidity in NHL is unknown. Here, we demonstrate that the three-category TRES and five-category NHL-5 scores perform as well as the 14-16 category CCI and NCI scores in terms of association with OS and lymphoma-specific survival. These simple scores could be more easily used in clinical practice without prognostic loss.


  • A phase 1 study of interleukin-15 in combination with avelumab in relapsed or refractory T-cell lymphoma

    by Max J. Gordon, Sigrid Dubois, Bonita Bryant, Samuel Ng, Kevin Conlon, Milos D. Miljkovic, Thomas Waldmann, Mark Roschewski


  • Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study

    by Max J. Gordon, Lei Feng, Paolo Strati, Hun Ju Lee, Fredrick B. Hagemeister, Jason R. Westin, Felipe Samaniego, Mario L. Marques‐Piubelli, Francisco Vega Vazquez, Edwin R. Parra Cuentas, et al.

    Background: Follicular lymphoma (FL) and marginal zone lymphoma (MZL) are indolent non‐Hodgkin lymphomas (iNHL). Median survival for iNHL is approximately 20 years. Because standard treatments are not curative, patients often receive multiple lines of therapy with associated toxicity—rationally designed, combination therapies with curative potential are needed. The immunomodulatory drug lenalidomide was evaluated in combination with rituximab for the frontline treatment of FL in the phase 3 RELEVANCE study. Ibrutinib, an oral Bruton tyrosine kinase inhibitor, is active in NHL and was evaluated in combination with lenalidomide, rituximab, and ibrutinib (IRR) in a phase 1 study.Methods: The authors conducted an open‐label, phase 2 clinical trial of IRR for previously untreated FL and MZL. The primary end point was progression‐free survival (PFS) at 24 months.Results: This study included 48 participants with previously untreated FL grade 1–3a (N = 38), or MZL (N = 10). Participants received 12, 28‐day cycles of lenalidomide (15 mg, days 1–21 cycle 1; 20 mg, cycles 2–12), rituximab (375 mg/m2 weekly in cycle 1; day 1 cycles 2‐12), and ibrutinib 560 mg daily. With a median follow‐up of 65.3 months, the estimated PFS at 24 months was 78.8% (95% confidence interval [CI], 68.0%–91.4%) and 60‐month PFS was 59.7% (95% CI, 46.6%–76.4%). One death occurred unrelated to disease progression. Grade 3–4 adverse events were observed in 64.6%, including 50% with grade 3–4 rash.Conclusions: IRR is highly active as frontline therapy for FL and MZL. Compared to historical results with lenalidomide and rituximab, PFS is similar with higher grade 3–4 toxicity, particularly rash. The study was registered with ClinicalTrials.gov (NCT02532257).


  • Influence of treatment intensity and medical comorbidities in older adults with peripheral T cell lymphoma

    by Max J. Gordon, Zhigang Duan, Hui Zhao, Loretta Nastoupil, Samuel Ng, Alexey V. Danilov, Swaminathan Iyer, Sharon H. Giordano

    We conducted a population-based study of patients >65 years, diagnosed 2008-2017, with peripheral T-cell lymphoma (PTCL) using SEER-Medicare. Associations between PTCL subtype, treatment regimen, comorbidity, and mortality were assessed using the Kaplan-Meier method and multivariable Cox regression. Amongst the 2,546 patients, the median age was 77 years (interquartile range, 71-83). 5-year overall survival (OS) ranged from 22.2% to 37.3% depending on PTCL subtype. The most common frontline regimen was cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). 5-year OS rate was 47.0% for patients treated with etoposide + CHOP (N = 67; CHOEP), 33.7% for those treated with CHOP (N = 732), and 23.8% for patients treated with non-anthracycline-containing regimens (N = 105; p < 0.001). In patients without comorbidities, CHOEP remained independently associated with improved OS (HR 0.52, 95% CI,0.30-0.91). Median OS was 1.2 years from initiation of second-line therapy (N = 228) independent of treatment regimen. Frontline but not second-line treatment regimen is associated with OS in older patients with PTCL.